Shangdong Dong-E Spins Off Donkey Meat Business
This article was originally published in PharmAsia News
Shangdong Dong-E E-Jiao Group's foray into the donkey meat business has received orders worth over 40 million yuan since its entry in 2007. Targeting sales of 600 million yuan over the next three years, the firm has invested 120 million yuan to make it China's top brand. The spinoff business arose from Dong-E's bid to secure more donkey-hide gelatin, a pharmaceutical raw material in short supply. In fact, many traditional Chinese medicine enterprises face the same problem of limited supply; experts advise that these companies should consider extending their strategy to upstream raw materials like what Dong-E is doing. (Click here for more - Chinese Language)
You may also be interested in...
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.